Women's Health
Basic InformationLatest News
Why Quitting Smoking Might Be a Bit Tougher for WomenCleaner Air Could Mean Healthier Brains for Older WomenImmune-Based Drug Fights Advanced Endometrial Cancer: StudyBreastfeeding May Protect a Mom's Heart Years LaterAHA News: Pregnant Women Living Under Negative Social Conditions May Face Higher Heart Disease RiskFour Factors in Midlife Predict a Healthy Old Age for WomenYou Can Help Prevent Cervical CancerCOVID Vaccine May Temporarily Add 1 Day to Menstrual Cycle: StudyCould New Blood Test Predict Pregnancy Complications?Unhealthy Heart May Be Bigger Threat to Women's Brains Than Men'sNew Clues to How Ovarian Cancer Begins -- and Might Be PreventedMore U.S. Women Are Retaining Their Hearing as They AgeWhy Are More Women Using Pot, Other Cannabis Products During Pregnancy?Chemicals in Hair, Beauty Products May Interfere With Hormones During PregnancyFDA Allows Abortion Pill to Stay Available by MailDrug Combo May Fight a Tough Form of Breast CancerStress May Be Stronger Trigger for Problem Drinking in Women Than MenRemoving Ovaries During Hysterectomy Before 50 Can Bring Health RisksGastro Symptoms of Menopause May Vary by RaceBlack Women Have Triple the Odds for Lymphedema After Breast Cancer SurgeryGene Test Spots Breast Cancer Patients Who Can Skip Post-Op ChemoHPV Vaccine Is Reducing Cervical Cancers in Teens, Young WomenPostpartum Depression Can Do Long-Term Harm to Women's FinancesFDA Approves Imaging Drug That Can Help Surgeons Spot Ovarian CancersMom's Pre-Pregnancy Weight Could Affect Odds for Child's Asthma, AllergiesCould Estrogen Help Shield Women's Brains From Alzheimer's?Women Feel More Stigma From 'Spare Tire' Around Middle Than MenHPV Vaccination When Young Cuts Cervical Cancer Risk by 87%Will an Early-Stage Breast Cancer Spread? New Analysis Offers Some AnswersWomen Less Likely to Ask for More Time When Deadlines LoomWhen Climbing Corporate Ladder, Women Are as Competitive as Men: Study'Forever Chemicals' Might Raise Risk of Pregnancy ComplicationFinancial Stress Burdens More Than Half of New U.S. Moms: StudyA Faster, Cheaper Test to Gauge the Risk of Premature Delivery?Could Breastfeeding Help Women Keep Their Smarts as They Age?Stronger Breast Implant Safety Measures Announced by FDAPTSD Symptoms May Vary Throughout Menstrual Cycle: StudyVision Troubles Could Raise Midlife Depression Risk for WomenToo Little Vitamin D Could Raise Colon Cancer Risk in Black WomenWhy Are Cases of Pancreatic Cancer Rising in Young Women?Depression, Anxiety Could Raise a Pregnant Woman's Odds for C-SectionStill Too Few Women in Stroke Treatment Clinical TrialsMore Middle-Aged, Older Women Getting  'Broken Heart' SyndromeFDA Warns Against Using At-Home Dermal Filler 'Pens'AHA News: Broken Heart Syndrome Is on the Rise, Especially Among Older WomenLengthening Menstrual Cycles Near Menopause Could Predict Heart HealthPandemic Stress Altered Many Women's Menstrual CyclesBreastfeeding Longer May Lower Postpartum Depression RiskAHA News: How Black Women Can Take Control of Their Blood PressureLow-Dose Aspirin Guards Against Preeclampsia: Task Force
LinksSelf-Help Groups
Related Topics

Wellness and Personal Development
Mental Disorders

Immune-Based Drug Fights Advanced Endometrial Cancer: Study

HealthDay News
by Cara Murez
Updated: Jan 13th 2022

new article illustration

THURSDAY, Jan. 13, 2022 (HealthDay News) -- A drug used to treat several types of cancer is also an effective treatment for aggressive forms of endometrial cancer, the second most common cancer in women worldwide, a new clinical trial shows. The endometrium is the inner lining of the uterus.

"These findings suggest a long-term benefit to patients," said lead researcher Dr. David O'Malley, a gynecologic oncologist at the Ohio State University Comprehensive Cancer Center, in Columbus. "Even the potential for curative intent is now possible in patients with recurrent or metastatic uterine cancer."

Pembrolizumab, marketed as Keytruda, inhibits cellular receptors that prevent the immune system from recognizing and destroying cancer cells. It is already used to treat melanoma, lung, head/neck, cervical and stomach cancers.

This mid-stage clinical trial included 90 women in 15 countries with recurrent or advanced endometrial cancer. Their cancers were MMR deficient (dMMR) or MSI-high tumors, meaning they behave abnormally.

According to the new report, 48% of patients with advanced endometrial cancer experienced a complete or partial response to treatment. In two-thirds, the response lasted more than three years. Two-thirds of all patients in the study had a measurable response to treatment. The median follow-up was about 3.5 years — meaning half were followed for a shorter time, half longer.

The findings are timely because rates of endometrial cancer are on the rise. The cancer begins in the tissue lining the uterus. Platinum-based chemo drugs can be effective, but in many cases, cancer returns, the study authors noted in a university news release.

Effective therapies for cancer that has returned or spread are limited, according to the study team. As a result, the five-year survival rate for women with advanced or recurrent endometrial cancer is 17%.

Up to 31% of patients with endometrial cancer have changes in DNA known as microsatellite instability (MSI-H) and mismatch repair deficiency (dMMR). The change is usually present in the tumor and is not a genetic mutation, O'Malley noted.

"By targeting this damaged pathway with this targeted drug, we can reset the cellular mechanisms and allow the immune system to reactivate and attack the cancer cells," O'Malley said.

The researchers noted that before this study, there was no standard-of-care second-line therapy for endometrial cancer patients with MSI-H/dMMR-positive tumors. They said the response for this treatment is very strong overall when compared to the expected 10% to 15% response rate to the most often used second-line chemotherapy treatments.

The findings were published online recently in the Journal of Clinical Oncology.

Merck, which makes pembrolizumab, sponsored the study.

More information

The U.S. National Cancer Institute has more on endometrial cancer.

SOURCE: Ohio State University Wexner Medical Center, news release, Jan. 6, 2022

328 W. Claiborne St.
P.O. Box 964
Alabama 36460
Tel: (251)575-4203

powered by centersite dot net